<DOC>
	<DOCNO>NCT00656513</DOCNO>
	<brief_summary>RATIONALE : Acupuncture-like transcutaneous electrical nerve stimulation ( ALTENS ) pilocarpine may help relieve chronic xerostomia ( dry mouth ) . It yet know remedy effective treat chronic dry mouth cause radiation therapy patient head neck cancer . PURPOSE : This randomized phase II/III trial study ALTENS see well work compare pilocarpine treat chronic dry mouth cause radiation therapy patient head neck cancer .</brief_summary>
	<brief_title>Acupuncture-Like Transcutaneous Electrical Nerve Stimulation ( ALTENS ) Pilocarpine Treating Early Dry Mouth Patients Undergoing Radiation Therapy Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility successfully deliver acupuncture-like transcutaneous electrical nerve stimulation ( ALTENS ) use Codetron™ unit cooperative group set head neck cancer patient early radiotherapy-induced xerostomia . ( phase II ) - Compare efficacy ALTENS treatment v pilocarpine hydrochloride patient reduce overall xerostomia burden , measure University Michigan 15-item Xerostomia-Related Quality Life Scale ( XeQOLS ) 9 month randomization . ( phase III ) Secondary - Evaluate effect ALTENS treatment overall xerostomia burden 6 month study entry patient . ( phase II ) - Compare efficacy treatment patient reduce overall xerostomia burden 4 , 6 , 15 month randomization . ( phase III ) - Compare efficacy treatment patient reduce symptom burden , measure four domain XeQOLS ( i.e. , physical functioning , social functioning , personal/psychological functioning , pain/discomfort ) 4 , 6 , 9 , 15 month randomization . ( phase III ) - Compare efficacy treatment patient increase stimulate ( i.e. , citric acid prim ) whole salivary production ( WSP ) , measure sialometry , 4 , 6 , 9 , 15 month randomization . ( phase III ) - Compare efficacy treatment patient increase unstimulated ( i.e. , basal prim ) WSP , measure sialometry 4 , 6 , 9 , 15 month randomization . ( phase III ) - Compare adverse event associated treatment patient . ( phase III ) OUTLINE : This phase II follow phase III multicenter study . - Phase II : Patients undergo placement surface electrode follow acupuncture point : large intestine , spleen , stomach , conception vessel . Patients undergo acupuncture-like transcutaneous electrical nerve stimulation ( ALTENS ) point use Codetron™ unit 20 minute twice weekly 12 week . No treatment give 12 week . - Phase III : Patients stratify accord prior use pilocarpine ( vs yes ) length time completion chemotherapy and/or radiotherapy ( 3-6 month v 6-12 month v &gt; 12 month ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral pilocarpine three time daily 12 week absence disease progression unacceptable toxicity . - Arm II : Patients undergo ALTENS treatment use Codetron™ unit twice weekly 12 week absence disease progression unacceptable toxicity . Patients undergo quality life ( QOL ) assessment baseline 6 month registration phase II . In phase III patient complete assessment basal stimulate whole salivary production , xerostomia burden , QOL baseline 4 , 6 , 9 , 15 month study entry . After completion study therapy , patient follow 3 month . PROJECTED ACCRUAL : A total 45 patient accrue phase II portion 144 patient phase III portion study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis head neck cancer No clinical evidence disease recurrence ear , nose , throat exam nasopharyngeal scope , indicate , 8 week prior registration Completed radiotherapy ( i.e. , standard intensitymodulated radiotherapy ) without chemotherapy ≥ 3 month 2 year prior study entry Grade 12 radiotherapyinduced xerostomia accord NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) v.3.0 dry mouth/salivary gland xerostomia scale Must evidence residual salivary function unstimulated ( basal ) whole salivary production ≥ 0.1 ml/min refrain eat drink oral fluid 2 hour No patient normal saliva production ( i.e. , salivary gland change xerostomia ) No history serious adverse event prior treatment discontinuation pilocarpine No chronic lymphocytic leukemia PATIENT CHARACTERISTICS : See Disease Characteristics Zubrod performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy except nonmelanomatous skin cancer cancer patient diseasefree least 3 year ( e.g. , carcinoma situ breast , oral cavity , cervix ) No concurrent contraindication pilocarpine ( e.g. , uncontrolled asthma , miosis , hypersensitivity ) No severe , active comorbidity , include follow : Unstable cardiac disease requirement pacemaker insitu Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day prior registration Hepatic insufficiency result clinical jaundice and/or coagulation defect No Sjögren syndrome PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior pilocarpine cevimeline concurrent use ophthalmic nonophthalmic indication No concurrent regular medication induce xerostomia ( e.g. , tricyclic antidepressant , antihistamine anticholinergic effect , narcotic ) No concurrent oral stimulate agent salivary gland medical stimulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hypopharyngeal cancer</keyword>
	<keyword>laryngeal cancer</keyword>
	<keyword>lip oral cavity cancer</keyword>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>paranasal sinus nasal cavity cancer</keyword>
	<keyword>oropharyngeal cancer</keyword>
	<keyword>salivary gland cancer</keyword>
	<keyword>metastatic squamous neck cancer occult primary</keyword>
	<keyword>xerostomia</keyword>
	<keyword>tongue cancer</keyword>
</DOC>